[A20-14] Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Last updated 15.05.2020
Project no.:
A20-14
Commission:
Commission awarded on 17.02.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant
Negative effects outweigh positive effects; added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2020-08-20: G-BA decision was published.